title: Discrepant MR and [(18)F]Fluoroethyl-L-Tyrosine PET Imaging Findings in a Patient with Bevacizumab Failure.
abstract: Antiangiogenic treatment using bevacizumab may cause difficulties in distinguishing between antivascular and true antitumor effects when using MRI response criteria based on changes of contrast enhancement (i.e., Macdonald criteria). Furthermore, more precise tumor response assessment criteria (i.e., RANO criteria), which incorporate nonenhancing T2/FLAIR sequences into Macdonald criteria, may be influenced by other causes of T2/FLAIR hyperintensity (e.g., radiation-induced gliosis). The authors present discrepant MR and [(18)F]fluoroethyl-L-tyrosine PET imaging findings in a patient with bevacizumab treatment failure.
authors.affiliation: Institute of Neuroscience and Medicine, Forschungszentrum Juelich, Juelich ; Departments of Neurology, University Hospital Cologne, Cologne, Germany.
authors.forename: Norbert
authors.initials: N
authors.lastname: Galldiks
authors.forename: Christian P
authors.initials: CP
authors.lastname: Filss
authors.forename: Roland
authors.initials: R
authors.lastname: Goldbrunner
authors.forename: Karl-Josef
authors.initials: KJ
authors.lastname: Langen